Dr. Jackson attended Hampton University where she received her Bachelor of Science in Molecular Biology. She then obtained her MD from Eastern Virginia Medical School (EVMS). Dr. Jackson subsequently completed a residency in Pediatrics at Orlando Health and then completed a three-year fellowship in pediatric hematology/oncology at St. Jude Children’s Research Hospital. Additionally, she completed a two-year joint fellowship in pediatric neuro-oncology and clinical pharmacology at Johns Hopkins Medical Institute before being selected as an NCI Assistant Clinical Investigator in the Clinical Investigator Development Program in 2015.
Dr. Sadhana Jackson is a board-certified pediatrician and pediatric hematologist/oncologist with clinical expertise and research efforts related to the blood-brain barrier and malignant glioma. Dr. Jackson’s clinical practice focuses on drug delivery of systemic agents for pediatric malignant brain tumor patients. She has extensive experience with use of intracerebral microdialysis to evaluate optimal drug entry in malignant tumors.
As an Investigator in NINDS, Dr. Jackson ties her clinical practice to her research efforts focused on understanding the heterogeneous permeability of the blood-brain barrier amongst malignant gliomas. With her laboratory and clinical studies, her team aims to modulate the tumor microenvironment to enhance effective treatments to the CNS for malignant gliomas. Using exquisite tools to measure drug concentrations and agents to transiently disrupt the BBB, her research aims to maximize therapies for prolonged survival in aggressive pediatric brain tumors.
One of the major obstacles to effectively treating central nervous system (CNS) tumors is the integrity of the blood-brain barrier (BBB). The BBB prevents systemic drug delivery from reaching the brain and brain tumor tissue. While previous studies have mainly focused on circumventing the BBB, very few agents or mechanisms have been explored that modulate the tumor microenvironment to enhance effective therapies for malignant brain tumors. Our studies focus on understanding the heterogeneity of BBB permeability amongst malignant tumor cells and the role of the supportive BBB in tumor growth. Our collaborative laboratory and clinical investigations center around BBB biology, cancer biology, pharmacokinetics and pharmacodynamics related to optimal CNS drug delivery.